Pharmala Biotech Holdings Inc. (CSE:MDMA)

Pharmala Biotech Holdings Financials Overview

Financials in millions CAD. Fiscal year is September - August.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Revenue Revenue Growth	1.27	0.61	1.04	0.53	0.08	-
Revenue Growth	201.24%	-41.52%	94.60%	581.44%	-	-
Gross Profit Gross Profit Growth	1	0.55	0.89	0.45	0.08	-
Operating Income Operating Income Growth	-1.42	-2.01	-0.58	-0.67	-0.88	-0.58
Net Income Net Income Growth	-1.61	-2.18	-0.82	-0.78	-0.99	-3.76
Earnings Per Share EPS Growth	-0.02	-0.02	-0.01	-0.01	-0.01	-0.12
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023
Canada Canada Growth	0.01	0.03	0.07	0.01
United States United States Growth	0.52	0.35	0.03	-
Australia Australia Growth	-	0.23	0.84	0.42
Unallocated Unallocated Growth	-	-	0.09	-
Total Total Growth	1.26	0.61	1.04	0.53

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Net Cash (Debt) Net Cash Growth	0.25	0.96	0.42	0.2	0.85	2.47
Net Cash Growth	-79.99%	129.07%	115.02%	-77.11%	-65.53%	-
Net Cash Per Share Net Cash Per Share Growth	0.00	0.01	0.00	0.00	0.01	0.08
Cash & Investments Cash & Investments Growth	0.25	0.96	0.42	0.2	0.85	2.47

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-0.97	-1.04	-0.32	-0.34	-0.63	-0.26
Capital Expenditures CapEx Growth	-0	-0	-	-	-0	-0
Free Cash Flow Free Cash Flow Growth	-0.97	-1.05	-0.32	-0.34	-0.63	-0.26
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Gross Margin	79.02%	91.22%	85.72%	85.36%	97.07%	-
Operating Margin	-112.07%	-331.97%	-55.73%	-125.74%	-1127.69%	-
Pretax Margin	-126.87%	-359.25%	-79.55%	-146.58%	-1262.43%	-
Profit Margin	-126.87%	-359.25%	-79.55%	-146.58%	-1262.43%	-
FCF Margin	-76.63%	-172.85%	-31.04%	-63.84%	-804.87%	-

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 10, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
PS Ratio	12.06	23.77	7.53	35.60	53.16	-

Data Source: S&P Global Market Intelligence Last updated: May 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 10, 2026

Data Sources Report a data error